Midwest Trust Co Increases Stake in AbbVie Inc. $ABBV

Key Points

• Midwest Trust Co. increased its AbbVie stake by 0.9% in the second quarter, adding 4,215 shares to hold 489,495 shares valued at approximately $123.2 million. Institutional investors collectively own 70.23% of the company.
• AbbVie exceeded quarterly expectations with EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year, and issued third-quarter EPS guidance of $3.84–$3.88. Analysts maintain a “Moderate Buy” consensus with an average price target near $275.95.
• The company’s growth outlook is supported by new oncology and aesthetics pipeline developments, while the early termination of a long-term emraclidine study adds uncertainty to its neuroscience programs. AbbVie also pays a quarterly dividend of $1.73, yielding approximately 2.6% annually.

Midwest Trust Co raised its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 0.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 489,495 shares of the company's stock after purchasing an additional 4,215 shares during the quarter. AbbVie accounts for 1.4% of Midwest Trust Co's portfolio, making the stock its 15th biggest position. Midwest Trust Co's holdings in AbbVie were worth $123,177,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ABBV. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after buying an additional 45 shares during the period. Legacy Wealth Managment LLC ID grew its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after acquiring an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new stake in AbbVie in the 4th quarter worth $31,000. Finally, Abound Financial LLC purchased a new position in shares of AbbVie in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

AbbVie Trading Up 0.2%

Shares of ABBV opened at $265.62 on Monday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The firm's 50-day moving average price is $248.48 and its 200-day moving average price is $227.50. The firm has a market capitalization of $469.29 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 0.88 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie's dividend payout ratio is currently 195.48%.

Analysts Set New Price Targets

Several equities analysts have recently commented on ABBV shares. Barclays upped their price objective on shares of AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. UBS Group upped their price target on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Monday, July 13th. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. Finally, Cantor Fitzgerald boosted their target price on AbbVie from $265.00 to $285.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $275.95.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source